StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Oncology Portfolio Total [legacy incl. Oncology by Quarter

Oncology Portfolio Total [legacy incl. Oncology Biosimilars, through Q4 2025] ($M) ($M)

QuarterlyAnnual

Pfizer Oncology Portfolio Total [legacy incl. Oncology: $4,435M in Q4 2025, up 9.1% from a year earlier. That is the highest of the 37 quarters on record here.

Latest, Q4 2025
4,435
Period ended Dec 31, 2025
Change on a year earlier
+9.1%
4,064 in Q4 2024
History
37 quarters
Since Q4 2016
Sources
33
Documents cited below

Where the Q4 2025 figure comes from

“|| Oncology | $ | 4,435 | $ | 4,064 | 9% | 8% | $ | 3,327 | $ | 3,051 | 9% | $ | 1,108 | $ | 1,012 | 9% | 7%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

In Q1 2026, Oncology Biosimilars moved from Oncology into the new Global Hospital & Biosimilars portfolio.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOncology Portfolio Total [legacy incl. Oncology Biosimilars, through Q4 2025] ($M) ($M)Year on yearSource
Q4 2025Dec 31, 20254,435+9.1%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 20254,253+5.2%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 20254,387+10.9%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2025Mar 30, 20253,758+5.9%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2024Dec 31, 20244,064+27.4%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 20244,043+29.8%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 20243,956+25.6%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 20243,549+18.4%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 20233,189+6.1%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 20233,115+1.5%Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2023Jul 2, 20233,149+2.0%Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2023Apr 2, 20232,997+1.0%Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2022Dec 31, 20223,007-7.2%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2022Oct 2, 20223,070-0.5%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2022Jul 3, 20223,088-1.8%Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2022Apr 3, 20222,967+3.7%Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗

Breakdown

What makes up oncology Portfolio Total [legacy incl. Oncology

Cite this data

StockData. (2026). Pfizer Oncology Portfolio Total [legacy incl. Oncology ($M), quarterly Q4 2016–Q4 2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/port-leg-onc-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.